Today we’re launching a revised grants programme, to help make sure everyone with cystic fibrosis (CF) has the support they need to deal with the financial pressures that living with the condition can bring. Becky Kilgariff, Head of Information and Support at the Trust, writes about some of the changes we’ve made and how the programme will meet the needs of those who need our support the most in these challenging times.
The Trust’s Clinical Trials Accelerator Platform (CTAP) has received £5.2 million of funding from the USA’s Cystic Fibrosis Foundation to expand access to clinical trials and accelerate the development of new treatments as we unite for a life unlimited, for everyone with cystic fibrosis.
We work hard to ensure that everything we do makes the biggest difference possible to people with cystic fibrosis (CF) and their families. Find out more about the work of Cystic Fibrosis Trust today.
The Trust is dedicated to supporting our community to manage the emotional and psychological pressures of cystic fibrosis (CF). You can find further information on managing your own mental health or how to support others here.
We recently launched a new project to break down some of the barriers people from Black, Asian and minority ethnic communities can face when it comes to accessing CF clinical trials. In this blog, Loren from our Clinical Trials Accelerator Platform team, shares more about this project, why it’s important, and our ongoing commitment to make sure everybody with CF can live a life unlimited.
The Cystic Fibrosis Trust has been working with NHS England and the UK CF Medical Association (UKCFMA) to support the roll out of home monitoring devices and apps to help people with CF stay well at home and spot health problems early during the coronavirus (COVID-19) pandemic.
This week Vertex will meet with NHS England on Wednesday 25 April to discuss further negotiations around access to precision medicine Orkambi and similar future cystic fibrosis (CF) treatments. Lynsey Beswick, Public Affairs Manager at the Cystic Fibrosis Trust, explains what’s happened since last month’s debate in Parliament and what the next steps are for the campaign.
The European Medicines Agency (EMA) has today given marketing authorisation for new cystic fibrosis (CF) medicine Symkevi. This important milestone means that, if an agreement can be reached between the NHS and the manufacturer, Vertex Pharmaceuticals, the treatment could be available for people with CF in the UK.
